Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Dublin, Aug. 11, 2017 -- The "Seasonal Influenza Vaccines" report has been added to Research and Markets' offering.
Seasonal influenza is an acute viral infection that is spread by person-to-person transmission. Influenza, commonly referred to as the flu, circulates worldwide and can affect anyone in any age group, although annual epidemics peak during winter in temperate climates. Seasonal influenza can be type A, B, or C. Type A influenza viruses are considered to be the most virulent of the three types and can be further classified by serotype based on antibody response to the virus.
Seasonal influenza presents significant public health problems for nearly every country, largely because of the cost associated with the treatment or management of the disease, as well as the toll on the workforce. Vaccination against seasonal influenza is the most effective method of preventing influenza infection. However, global vaccination rates remain lower than the levels recommended by the World Health Organization.
Recent events and opinion:
- Quadrivalent vaccines are seeing rapid uptake and will gradually replace trivalent vaccines in all patient groups in the US and EU markets
- The broadening of recommendations to include school-aged children will drive EU market growth significantly
- Adjuvanted vaccines in development have the potential to address unmet needs in infants and the elderly
Key Topics Covered:
Forecast: Seasonal Influenza Vaccines
Executive Summary
- Market Overview and Trends
- Key Drivers and Resistors of Conversion to QIVs
- Market Definition
- US Market Forecast
- France Market Forecast
- Germany Market Forecast
- Italy Market Forecast
- Spain Market Forecast
- UK Market Forecast
Marketed Drugs: Seasonal Influenza Vaccines
- Executive Summary
- Product Overview
- Product profile: FluMist QIV
- Product profile: Flucelvax QIV
- Product profile: Fluzone High-Dose
Pipeline: Seasonal Influenza Vaccines
- Executive Summary
- Clinical Pipeline Overview
- Product profile (late stage): Fluad QIV
For more information about this report visit https://www.researchandmarkets.com/research/gz6m4x/seasonal
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Vaccines
